Tolerability of raltitrexed ('Tomudex') in elderly patients with colorectal cancer

Adriana Romiti, Giuseppe Tonini, Daniele Santini, Marisa Di Seri, Raffaele Masciangelo, Silvia Mezi, Attilio Verì, Lucia Santuari, Bruno Vincenzi, Antonio Brescia, Paolo Marchei, Luigi Frati, Silverio Tomao

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: Colorectal cancer (CRC) is one of the major health problems of the Western world and the proportion of elderly patients with CRC is growing. Raltitrexed ('Tomudex'), a specific thymidylate synthase inhibitor, has shown efficacy and manageable toxicity in elderly CRC patients. In this retrospective study, the tolerability of raltitrexed in patients with CRC was examined in relation to age. Patients and Methods: Toxicity parameters, graded according to World Health Organization criteria, were assessed in two patient groups: 2 as a 15-minute intravenous infusion every 3 weeks) were aged >70 years (M:F 28:22; Eastern Cooperative Oncology Group performance status 0-1:2 38:12). Results: Overall, 437 cycles of chemotherapy were administered and grade 3-4 toxicity was reported in

Original languageEnglish
Pages (from-to)3071-3076
Number of pages6
JournalAnticancer Research
Volume22
Issue number5
Publication statusPublished - Sep 2002

Fingerprint

Colorectal Neoplasms
Thymidylate Synthase
Western World
Intravenous Infusions
Retrospective Studies
raltitrexed
Drug Therapy
Health

Keywords

  • Chemotherapy
  • Colorectal cancer
  • Elderly
  • Raltitrexed

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Romiti, A., Tonini, G., Santini, D., Di Seri, M., Masciangelo, R., Mezi, S., ... Tomao, S. (2002). Tolerability of raltitrexed ('Tomudex') in elderly patients with colorectal cancer. Anticancer Research, 22(5), 3071-3076.

Tolerability of raltitrexed ('Tomudex') in elderly patients with colorectal cancer. / Romiti, Adriana; Tonini, Giuseppe; Santini, Daniele; Di Seri, Marisa; Masciangelo, Raffaele; Mezi, Silvia; Verì, Attilio; Santuari, Lucia; Vincenzi, Bruno; Brescia, Antonio; Marchei, Paolo; Frati, Luigi; Tomao, Silverio.

In: Anticancer Research, Vol. 22, No. 5, 09.2002, p. 3071-3076.

Research output: Contribution to journalArticle

Romiti, A, Tonini, G, Santini, D, Di Seri, M, Masciangelo, R, Mezi, S, Verì, A, Santuari, L, Vincenzi, B, Brescia, A, Marchei, P, Frati, L & Tomao, S 2002, 'Tolerability of raltitrexed ('Tomudex') in elderly patients with colorectal cancer', Anticancer Research, vol. 22, no. 5, pp. 3071-3076.
Romiti A, Tonini G, Santini D, Di Seri M, Masciangelo R, Mezi S et al. Tolerability of raltitrexed ('Tomudex') in elderly patients with colorectal cancer. Anticancer Research. 2002 Sep;22(5):3071-3076.
Romiti, Adriana ; Tonini, Giuseppe ; Santini, Daniele ; Di Seri, Marisa ; Masciangelo, Raffaele ; Mezi, Silvia ; Verì, Attilio ; Santuari, Lucia ; Vincenzi, Bruno ; Brescia, Antonio ; Marchei, Paolo ; Frati, Luigi ; Tomao, Silverio. / Tolerability of raltitrexed ('Tomudex') in elderly patients with colorectal cancer. In: Anticancer Research. 2002 ; Vol. 22, No. 5. pp. 3071-3076.
@article{0795fc5a2b4746f1996e9532f500b76f,
title = "Tolerability of raltitrexed ('Tomudex') in elderly patients with colorectal cancer",
abstract = "Purpose: Colorectal cancer (CRC) is one of the major health problems of the Western world and the proportion of elderly patients with CRC is growing. Raltitrexed ('Tomudex'), a specific thymidylate synthase inhibitor, has shown efficacy and manageable toxicity in elderly CRC patients. In this retrospective study, the tolerability of raltitrexed in patients with CRC was examined in relation to age. Patients and Methods: Toxicity parameters, graded according to World Health Organization criteria, were assessed in two patient groups: 2 as a 15-minute intravenous infusion every 3 weeks) were aged >70 years (M:F 28:22; Eastern Cooperative Oncology Group performance status 0-1:2 38:12). Results: Overall, 437 cycles of chemotherapy were administered and grade 3-4 toxicity was reported in",
keywords = "Chemotherapy, Colorectal cancer, Elderly, Raltitrexed",
author = "Adriana Romiti and Giuseppe Tonini and Daniele Santini and {Di Seri}, Marisa and Raffaele Masciangelo and Silvia Mezi and Attilio Ver{\`i} and Lucia Santuari and Bruno Vincenzi and Antonio Brescia and Paolo Marchei and Luigi Frati and Silverio Tomao",
year = "2002",
month = "9",
language = "English",
volume = "22",
pages = "3071--3076",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Tolerability of raltitrexed ('Tomudex') in elderly patients with colorectal cancer

AU - Romiti, Adriana

AU - Tonini, Giuseppe

AU - Santini, Daniele

AU - Di Seri, Marisa

AU - Masciangelo, Raffaele

AU - Mezi, Silvia

AU - Verì, Attilio

AU - Santuari, Lucia

AU - Vincenzi, Bruno

AU - Brescia, Antonio

AU - Marchei, Paolo

AU - Frati, Luigi

AU - Tomao, Silverio

PY - 2002/9

Y1 - 2002/9

N2 - Purpose: Colorectal cancer (CRC) is one of the major health problems of the Western world and the proportion of elderly patients with CRC is growing. Raltitrexed ('Tomudex'), a specific thymidylate synthase inhibitor, has shown efficacy and manageable toxicity in elderly CRC patients. In this retrospective study, the tolerability of raltitrexed in patients with CRC was examined in relation to age. Patients and Methods: Toxicity parameters, graded according to World Health Organization criteria, were assessed in two patient groups: 2 as a 15-minute intravenous infusion every 3 weeks) were aged >70 years (M:F 28:22; Eastern Cooperative Oncology Group performance status 0-1:2 38:12). Results: Overall, 437 cycles of chemotherapy were administered and grade 3-4 toxicity was reported in

AB - Purpose: Colorectal cancer (CRC) is one of the major health problems of the Western world and the proportion of elderly patients with CRC is growing. Raltitrexed ('Tomudex'), a specific thymidylate synthase inhibitor, has shown efficacy and manageable toxicity in elderly CRC patients. In this retrospective study, the tolerability of raltitrexed in patients with CRC was examined in relation to age. Patients and Methods: Toxicity parameters, graded according to World Health Organization criteria, were assessed in two patient groups: 2 as a 15-minute intravenous infusion every 3 weeks) were aged >70 years (M:F 28:22; Eastern Cooperative Oncology Group performance status 0-1:2 38:12). Results: Overall, 437 cycles of chemotherapy were administered and grade 3-4 toxicity was reported in

KW - Chemotherapy

KW - Colorectal cancer

KW - Elderly

KW - Raltitrexed

UR - http://www.scopus.com/inward/record.url?scp=0036765690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036765690&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 3071

EP - 3076

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -